Транскатетерная симпатическая денервация почек в лечении резистентной артериальной гипертензии: современное состояние вопроса

1. Шальнова С.А., Конради А.О., Карпов Ю.А. и др. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской Федерации, участвующих в исследовании «Эпидемиология сердечно-сосудистых заболеваний в различных регионах России». Рос. кардиол. журн. 2012; 5: 6–11. / Shal'nova S.A., Konradi A.O., Karpov Iu.A. i dr. Analiz smertnosti ot serdechno-sosudistykh zabolevanii v 12 regionakh Rossiiskoi Federatsii, uchastvuiushchikh v issledovanii “Epidemiologiia serdechno-sosudistykh zabolevanii v razlichnykh regionakh Rossii”. Ros. kardiol. zhurn. 2012; 5: 6–11. [in Russian]
2. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization, 2009; p. 1–62.
3. Kearney PM et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–23.
4. Freis E. Hypertension: Pathophysiology, Diagnosis and Management. 2nd ed. New York: Raven Press, 1995.
5. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012; 125: 1594–6.
6. Daugherty SL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125 (13): 1635–42. DOI: 10.1161/CIRCULATIONAHA.111.068064
7. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403–19.
8. Calhoun DA, Booth JN 3rd, Oparil S et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014; 63: 451–8.
9. Ohman EM, Bhatt DL, Steg PG et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006; 151 (4): 786.e1–10.
10. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens 2015; 28: 355–61.
11. Esler M, Jennings G, Korner B et al. Measurement of total and organ-specific nor-epinephrine kinetics in humans. Am J Physiol 1984; 247: 21–8.
12. Kottke FJ, Kubicek WG, Visscher MB. The production of arterial hypertension by chronic renal artery – nerve stimulation. Am J Phisiol 1945; 145: 38–47.
13. Grimson KS, Orgain ES, Anderson B et al. Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy. Ann Surg 1949; 129: 850–71.
14. Smithwick R, Thompson J. Splanchnicectomy for essential hypertension: results in 1,266 cases. J Am Med Assoc 1953; 152: 1501–4.
15. DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension 2004; 43: 147–50.
16. Ланг Г.Ф. Гипертоническая болезнь. М.: Медгиз, 1950; с. 496. / Lang G.F. Gipertonicheskaia bolezn'. M.: Medgiz, 1950; s. 496. [in Russian]
17. Julius S, Krause L, Schork NJ et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertension 1989; 14: 177–83.
18. Müller J, Barajas L. Electron microscopic and histochemical evidence for a tubular innervation in the renal cortex of the monkey. J Ultrastruct Res 1972; 41 (5): 533–49.
19. Barajas L, Müller J. The innervation of the juxtaglomerular apparatus and surrounding tubules: a quantitative analysis by serial section electron microscopy. J Ultrastruct Res 1973; 43 (1): 107–32.
20. Esler M, Jennings G, Korner P et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988; 11: 3–20.
21. Lambert E, Straznicky N, Schlaich M et al. Differing patterns of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension 2007; 50: 862–8.
22. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724–8.
23. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012; 33: 1058–66.
24. DiBona G. Neural control of the kidney: functionally specific renal sympathetic nerve fibers. Am J Physiol 2000; 279: R1517–R1524.
25. DiBona G, Kopp U. Neural control of renal function. Physiol Rev 1997; 77: 75–197.
26. Osborn JW, Foss JD. Renal nerves and long-term control of arterial pressure. Compr Physiol 2017; 7: 263–320. DOI: 10.1002/cphy.c150047
27. Campese VM, Ku E, Park J. Sympathetic renal innervations and resistant hypertension. Int J Hypertens 2011; 2011: 814354.
28. Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559–65.
29. Zaldivia MT, Rivera J, Hering D et al. Renal denervation reduces monocyte activation and monocyte-platelet aggregate formation: an anti-inflammatory effect relevant for cardiovascular risk. Hypertension 2017; 69: 323–31. DOI: 10.1161/HYPERTENSIONAHA.116.08373
30. Bhatt D, Bakris G. The promise of renal denervation. Cleveland Clin J Med 2012; 79: 498–500.
31. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol 2010; 105: 570–6.
32. Egan B. Renal sympathetic denervation: a novel intervention for resistant hypertension, insulin resistance, and sleep apnea. Hypertension 2011; 58: 542–3.
33. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomized controlled trial. Lancet 2010; 376: 1903–9.
34. Rehman J, Landman J, Lee D et al. Needle-based ablation of renal parenchyma using microwave, cryoablation, impedance- and temperature-based monopolar and bipolar radiofrequency, and liquid and gel chemoablation: laboratory studies and review of the literature. J Endourol 2004; 18 (1): 83–104.
35. Koopmann M, Shea J, Kholmovski E et al. Renal sympathetic denervation using MR-guided high-intensity focused ultrasound in a porcine model. J Ther Ultrasound 2016; 4: 3. Published online 2016 Feb 3. DOI: 10.1186/s40349-016-0048-9
36. Rossi NF, Pajewski R, Chen H et al. Hemodynamic and neural responses to renal denervation of the nerve to the clipped kidney by cryoablation in two-kidney, one-clip hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2016; 310: R197–R208. DOI: 10.1152/ajpregu.00331.2015
37. Harris W. Alcohol injection of the Gasserian ganglion for trigeminal neuralgia. Lancet 1912; 179: 218–21.
38. Iaccarino V, Russo D, Niola R et al. Total or partial percutaneous renal ablation in the treatment of renovascular hypertension: radiological and clinical aspects. Br J Radiol 1989; 62: 593–8.
39. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37: 616–23.
40. Manning PT, Powers CW, Schmidt RE et al. Guanethidine induced destruction of peripheral sympathetic neurons occurs by an immune-mediated mechanism. J Neurosci 1983; 3: 714–24.
41. Stefanadis C, Synetos A, Toutouzas K et al. New double balloon delivery catheter for chemical denervation of the renal artery with vincristine. Int J Cardiol 2013; 168: 4346–8.
42. Stefanadis C, Toutouzas K, Vlachopoulos C et al. Chemical denervation of the renal artery with vincristine for the treatment of resistant arterial hypertension: first-in-man application. Hellenic J Cardiol 2013; 54: 318–21.
43. Fischell TA, Ebner A, Gallo S et al. Transcatheter Alcohol-Mediated Perivascular Renal Denervation With the Peregrine System: First-in-Human.
44. Norvell JE. The aorticorenal ganglion and its role in renal innervation. J Comp Neurol 1968; 133: 101–12.
45. Lusch A, Leary R, Heidari E et al. Intrarenal and extrarenal autonomic nervous system redefined. J Urol 2014; 191: 1060–5.
46. Atherton DS, Deep NL, Mendelshon FO. Micro-anatomy of the renal sympathetic nervous system: A human postmortem histologic study. Clin Anat 2011; 25: 628–33.
47. Sakakura K, Ladich E, Cheng Q et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol 2014; 64: 635–43.
48. Mompeo B, Maranillo E, Garcia-Touchard et al. The Gross Anatomy of the Renal Sympathetic Nerves Revisited. Clin Anat 2016; 29: 660–4.
49. Okada T, Pellerin O, Savard S et al. Eligibility for renal denervation: Anatomical classification and results in essential resistant hypertension. Cardiovasc Intervent Radiol 2015; 38: 79–87.
50. Ozkan U, Oguzkurt L, Tercan F et al. Renal artery origins and variations: angiographic evaluation of 855 consecutive patients. Diag Interv Radiol 2006; 12: 183–6.
51. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000; 13: 99–105S.
52. Steigerwald K, Titova A, Malle C et al. Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model. J Hypertens 2012; 30: 2230–9.
53. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373 (9671): 1275–81.
54. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903–9.
55. Mahfoud F, Cremers B, Janker J et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60: 419–24. DOI: 10.1161/HYPERTENSIONAHA.112.193870
56. Ewen S, Cremers B, Meyer MR et al. Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. J Hypertens 2015; 33: 2519–25. DOI: 10.1097/HJH. 0000000000000752
57. Brinkmann J, Heusser K, Schmidt BM et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult to-control hypertensive patients: prospective case series. Hypertension 2012; 60 (6).
58. Pedrosa RP, Drager LF, Gonzaga CC et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011; 58: 811–7. 
59. Grassi G, Seravalle G, Brambilla G et al. Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects. Hypertension 2015; 65: 1209–16. DOI: 10.1161/HYPERTENSIONAHA.114.04823
60. Fink GD, Phelps JT. Can we predict the blood pressure response to renal denervation? Auton Neurosci 2017; 204: 112–8. DOI: 10.1016/j.autneu.2016.07.011
61. Esler M. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens 2014; 8: 593–8. DOI: 0.1016 /j.jash.2014. 06.001
62. Kandzari DE, Bhatt DL, Brar S et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2015; 36: 219–27.
63. Nakagawa H, Yamanashi WS, Pitha JV et al. Comparison of in vivo tissue temperature profile and lesion geometry for radiofrequency ablation with saline-irrigated electrode versus temperature control in a canine thigh muscle preparation. Circulation 1995; 91: 2264–73.
64. Ammar S, Ladich E, Steigerwald K et al. Pathophisiology of renal denervation procedures: from renal nerve anatomy to procedural parameters. Eurointervention 2013; 9: R89–R95.
65. Foss JD, Wainford RD, Engeland WC et al. A novel method of selective ablation of afferent renal nerves by periaxonal application of capsaicin. Am J Physiol Regul Integr Comp Physiol 2015; 308: R112–R122.
66. Kandzari DE, Kario K, Mahfoud F et al. The SPYRAL HTN Global Clinical Trial Program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J 2016; 171: 82–91. DOI: 10.1016/j.ahj.2015.08.021
67. Mahfoud F, Bakris G, Bhatt DL et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J 2017; 38 (2): 93–100. DOI: 10.1093/eurheartj/ehw325
68. Townsend RR, Mahfoud F, Kandzari DE et al; SPYRAL HTN-OFF MED Trial Investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017; 390: 2160–70. DOI: 10.1016/S0140-6736(17)32281-X
69. Pekarskiy SE, Baev AE, Mordovin VF et al. Denervation of the distal renal arterial branches vs. conventional main renal artery treatment: a randomized controlled trial for treatment of resistant hypertension. J Hypertens 2017; 35: 369–75.
70. Fengler K, Ewen S, Hollriegel R et al. Blood pressure response to main artery and combined main renal artery plus branch renal denervation in patients with resistant hypertension. J Am Heart Assoc 2017; 6: e006196. DOI: 10.1161/JAHA. 117.006196
71. Azizi M, Sapoval M, Gosse P et al; Renal Denervation for Hypertension (DENERHTN) Investigators. Optimum and stepped care standardized antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomized controlled trial. Lancet 2015; 385: 1957–65. DOI: 10.1016/S0140-6736(14)61942-5
72. Fink GD, Phelps JT. Can we predict the blood pressure response to renal denervation? Auton Neurosci 2017; 204: 112–8. DOI: 10.1016/j.autneu.2016.07.011
73. Dörr O, Liebetrau C, Möllmann H et al. Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation. Hypertension 2014; 63: 984–90. DOI: 10.1161/ HYPERTENSIONAHA.113.02266
74. De Jong MR, Adiyaman A, Gal P et al. Renal nerve stimulation-induced blood pressure changes predict ambulatory blood pressure response after renal denervation. Hypertension 2016; 68: 707–14. DOI: 10.1161/HYPERTENSIONAHA.116.07492

________________________________________________

П.А.Болотов*1,2, С.П.Семитко1,2, В.П.Климов1,2, Н.В.Верткина2

1 ФГБОУ ДПО «Институт повышения квалификации» ФМБА России. 125310, Россия, Москва, Волоколамское ш., д. 91;
2 ГБУЗ «Городская клиническая больница им. В.В.Вересаева» Департамента здравоохранения г. Москвы. 127644, Россия, Москва, ул. Лобненская, д. 10
*dr.bolotov@mail.ru

________________________________________________